Drug Patents owned by Allergan Inc

1. List of Durysta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8629185 ALLERGAN INC 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof
Jul, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398707 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related implants
Apr, 2024

(1 year, 2 months from now)

US8673341 ALLERGAN INC Intraocular pressure reduction with intracameral bimatoprost implants
Feb, 2025

(2 years from now)

US9149428 ALLERGAN INC Processes for making cyclic lipid implants for intraocular use
Dec, 2026

(3 years from now)

US10441543 ALLERGAN INC Processes for making cyclic lipid implants for intraocular use
Dec, 2026

(3 years from now)

US8206737 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related methods
Apr, 2027

(4 years from now)

US7799336 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related methods
Apr, 2029

(6 years from now)

US9980974 ALLERGAN INC Prostamide-containing intraocular implants and methods of use thereof
Oct, 2034

(11 years from now)

US9492316 ALLERGAN INC Prostamide-containing intraocular implants and methods of use thereof
Oct, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 4, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in